| View |
UPitt SQL-SAL Liver Transfer |
This study set is a series of studies that were carried out as part of the transfer of the UPItt SQL-SAL liver model (references below) to the tissue Chip Testing Centers (TCTCs). The 'Reference Study' was carried out at UPitt as a baseline data set for comparison with data generated by the TCTCs. the 'Training Studies' were carried out at UPitt along with personnel from the TCTCs to learn the methods for preparing the model. The 'Tex-Val' studies were carried out at the Texas A&M TCTC.
The studies in the set are a good starting point for evaluating the portability of the model, using the Graphing and Reproducibility tools in the MPS-Db. |
gough |
|
| View |
Baseline SQL-SAL 1.5 |
For Sharing |
gough |
|
| View |
TAMU Sql-Sql studies |
share this data |
gough_tc |
|
| View |
Power Analysis Example |
Good example to use for evaluating the power analysis |
gough_tc |
|
| View |
TAMU SQL-SAL 1.5 testing |
All 3D model studies |
gough_tc |
|
| View |
Tex-Val Cardiac 2d vs 3d Primary Cells |
Comparison of studies |
mwc10 |
|
| View |
SQL-SAL MPS Liver Model Reproducibility Figure 1B & 1S |
Figure 1. (B) Pie charts showing study reproducibility for each type of the experiment (laboratory, cell type, or study type: 2D=hepatocyte monolayer cultures, 3D=LAMPS chips). Colors depict overall study reproducibility score (green=excellent, yellow=acceptable, red=poor). See details of each experiment and study reproducibility for each parameter in Supplemental Figure X. |
gough |
|
| View |
UPDDI EPA Tox Studies 2016 |
A series of studies to profile toxicity of 15 drugs |
gough_tc |
|
| View |
Training Sets |
Used for training the TCTCs |
gough |
|
| View |
SQL-SAL MPS Liver Model Reproducibility Figure 2S |
Data sets produced at the Texas A&M Tissue Chip Testing Center and at the University of Pittsburgh Drug Discovery Institute. |
gough |
|
| View |
SQL-SAL MPS Liver Model Reproducibility Figure 2 |
Figure 2. LAMPS reproducibility with respect to the (A) functional performance, (B) metabolic capacity, and (C) drug-induced effects across different laboratories. Experiments were performed in parallel in two laboratories (1=circles and 2=squares) independently, but using the same protocols and the same batch of primary human hepatocytes. |
gough |
|
| View |
UPDDI EPA Toxicity Study 2016 |
Profiles of a panel of 15 test drugs in the SQL-SAL 1.5 liver model, carried out as a series of 4 studies:
1. EPA1: 3 week study comparing Tolcapone and Entacapone
2. EPA 2: Eighteen day study assessing the the toxicity of Caffeine, Valproic Acid, Thalidomide, and Warfarin.
3. EPA 3: Eighteen day study assessing toxicity of Buspirone, Metoprolol, Methotrexate, and Rifampicin.
4. EPA 4: Eighteen day study assessing toxicity of Erythromycin, Famotidine, Levofloxacin, Rosiglitazone, and Trovafloxacin. |
gough |
1
|
| View |
Testing of the UPitt Liver Model by the Tex-Val TCTC |
The Tissue Chip Testing Center (TCTC) at Texas A&M (Tex-Val) tested the performance and reproducibility of the UPitt Liver Model SqlSal 1.5, which is the precursor of the UPitt LAMPS model.
*Tier 0: In this tier of testing, we investigated the binding of test compounds to proteins in the cell culture media.
*Tier 1a: This tier of testing was part of the 3D “Baseline” study to measure the secretome of cells seeded in the SQL-SAL tissue chip without any treatments.
*Tier 1b: This tier of testing was part of the 3D “Metabolism” study to measure the metabolic capacity of cells seeded in SQL-SAL tissue chips.
*Tier 1c: This tier of testing was part of the 3D “Toxicity” study to measure the effects of drugs on cells seeded in SQL-SAL tissue chips.
*Tier 2a: This tier of testing was part of the 3D “Baseline” studies to measure the secretome of cells seeded in SQL-SAL tissue chips.
*Tier 2b: This tier of testing was part of the 3D “Metabolism” studies to measure metabolic capacity of cells seeded in SQL-SAL tissue chips.
*Tier 2c: This tier of testing was part of the 3D “Toxicity” study to measure the effects of drugs on cells seeded in SQL-SAL tissue chips.
To optimally view the data in this study set, it is recommended to use the Grouping/Filtering: Study Parameters:Study selector to choose a single study, and the General Graph Properties: Plot Graph By selector to choose to plot by Chip, Group or Compound. |
gough |
|
| View |
MAFLD Drug Testing |
This data supports the publication:
Daniel Lefever FP, Mark Miedel, Johanna DiStefano, Tongying Shun, Lawrence Vernetti, Alexander Soto-Gutierrez, Sandarshan Singh Monga, Ramon Bataller, Jaideep Behari, Vijay Yechoor, Ivet Bahar, Albert, Gough, Andrew Stern, D. Lansing Taylor. An Integrated Quantitative Systems Pharmacology Platform Reveals Repurposable Drugs for Nonalcoholic Fatty Liver Disease. 2021:in preparation. |
gough |
|
| View |
kidney datasets with values |
|
jmaggiore |
|
| View |
Liver_Mimetas 2-lane_Exp.9_PHH (TF HU8373) ± NPCs with Midazolam |
|
YKato |
|
| View |
Muscle activation in G-node-integrated tissues |
|
cordovesalbert |
|